Department of Ophthalmology and Visual Science, University of Chicago Medical Center.
University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.
Curr Opin Ophthalmol. 2022 Jul 1;33(4):332-337. doi: 10.1097/ICU.0000000000000854.
Currently, the most widely used treatment for endothelial disease is endothelial replacement via endothelial keratoplasty. Increasingly selective techniques have allowed for increased safety and faster visual recovery. However, alternative treatment options that are lower in cost, require less surgical expertise, and rely less on tissue availability are needed. This review discusses established and emerging therapies for endothelial disease without keratoplasty.
Regenerative therapies that have been successful include Descemet stripping only and Descemet membrane transplants. Rho-kinase inhibitors promote cell proliferation, adhesion, and migration and appear to have a role in these treatments and possibly in the prevention of endothelial disease. Cell-based therapies and the development of an artificial endothelial implant have also demonstrated promising results.
There are numerous emerging treatments for endothelial disease that have proven successful. Advances in our understanding of disease pathogenesis on a cellular level will continue to expand possibilities for therapeutics.
目前,内皮疾病最广泛的治疗方法是通过内皮角膜移植术进行内皮替代。越来越多的选择性技术提高了安全性和更快的视力恢复。然而,需要成本更低、对手术专业知识要求更少、对组织可用性依赖更少的替代治疗选择。本文讨论了不进行角膜移植的内皮疾病的既定和新兴疗法。
已经成功的再生疗法包括仅撕除 Descemet 膜和 Descemet 膜移植。Rho 激酶抑制剂促进细胞增殖、黏附和迁移,并且似乎在这些治疗方法中以及在内皮疾病的预防中具有作用。基于细胞的疗法和人工内皮植入物的开发也显示出了有希望的结果。
有许多新兴的内皮疾病治疗方法已被证明是有效的。在细胞水平上对疾病发病机制的理解的进步将继续扩大治疗的可能性。